Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 27 JANUARY 2026

SBA Makes Changes To Annual Charges

Winston Taylor
Explore more from Winston Taylor

The U.S. Small Business Administration (the SBA) has announced that the annual fee charged to Small Business Investment Companies (SBICs) for debentures (the Annual Fee) will initially be 0.3440% for the fiscal year 2026.

United StatesCorporate/Commercial Law
Alan Roth
Alan Roth
Kate L. Price
Kate L. Price
Michael A. Domanico
Michael A. Domanico

The U.S. Small Business Administration (the SBA) has announced that the annual fee charged to Small Business Investment Companies (SBICs) for debentures (the Annual Fee) will initially be 0.3440% for the fiscal year 2026. Any SBICs that have outstanding SBA debentures from October 1, 2025 to January 20, 2026 will be required to pay this Annual Fee, even if those debentures were received from SBA in prior years. In addition, SBA announced that, beginning January 20, 2026, it will charge different Annual Fees based on whether an SBIC utilizes Standard Debentures or Accrual Debentures.

On January 20, 2026, the Annual Fee for Standard Debentures will decrease to 0.2500% and the Annual Fee for Accrual Debentures will increase to 0.9630%. The distinction between these two Annual Fees is intended to reflect the different terms and conditions of the two types of debentures. An SBIC that receives a commitment for debentures between January 20, 2026 and September 30, 2026

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP